Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 10, 2005 - Issue 2
Submit an article Journal homepage
58
Views
15
CrossRef citations to date
0
Altmetric
Review

Current and future pharmacological intervention for diabetic retinopathy

Grant M ComerIndiana University School of Medicine Department of Ophthalmology, 702 Rotary Circle, Indianapolis, IN 46202USATel: + 1 317 274 2128; Fax: +1 317 274 2277;E-mail: [email protected]
&
Thomas A CiullaMidwest Eye Institute Vitreoretinal Service, 201 Pennsylvania Parkway, Indianapolis, IN 46280USATel: + 1 317 817 1822; Fax: + 1 317 817 1898;E-mail: [email protected]
Pages 441-455 | Published online: 10 May 2005

Bibliography

  • COWIE C, EBERHARDT ME: Diabetes 1996 American Diabetes Association Vital Statistics Alexandria, VA, USA (1996).
  • D'AMICO D: The management of diabetic eye disease. N EngL J. Med. (1994) 331:95–106.
  • NATIONAL SOCIETY TO PREVENT BLINDNESS: Vision problems in the US: data analysis, definitions, data sources, detailed data tables, analyses, interpretation. New York, USA (1980).
  • SPEISER P, GITTELSOHN A. PATZ A: Studies on diabetic retinopathy, III: influence of diabetes on intramural pericytes. Arch. OphthalmoL (1968) 80:332–337.
  • ANSARI N, ZHANG W, FULEP E, MANSOUR A: Prevention of pericyte loss by trolox in diabetic rat retina. J. ToxicoL Environ. Health (1998) 54:467–475.
  • PAGET C, LECOMTE M, RUGGIERO D et al.: Modification of enzymatic antioxidants in retinal microvascular cells by glucose or advanced glycation end products. Free Radic. Biol. Med. (1998) 25:121–129.
  • ANTONELLI-ORLIDGE A, SMITH S, D'AMORE P: Influence of pericytes on capillary endothelial cell growth. Am. Rev. Respir. Dis. (1989) 140:1129–1131.
  • CIULLA T, HARRIS A, LATKANY P et al.: Ocular perfusion abnormalities in diabetes. Acta Ophthalmol. Scand. (2002) 80:468–477.
  • AIELLO L, AVERY R, ARRIGG P et al.: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N EngL J. Med. (1994) 331:1480–1487.
  • KUBAWARA T, COGAN D: Retinal vascular patterns, VI: mural cells of the retinal capillaries. Arch. OphthalmoL (1962) 69:492–502.
  • SIMS D: The pericyte - a review. Tissue Cell (1986) 18:153–174.
  • FOLKMAN J: Angiogenesis: inhibition and control. Ann. NY Acad. Sci. (1982) 401:212–227.
  • KLEIN R, KLEIN B, MOSS S et al.: The Wisconsin epidemiology study of diabetic retinopathy. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 or more years. Arch. OphthalmoL (1989) 107:244–249.
  • SANCHEZ-THORIN J: The epidemiology of diabetes mellitus and diabetic retinopathy. Intl. OphthalmoL Clin. (1998) 38(2):11–18.
  • THE DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N EngL J. Med. (1993) 329:977–986.
  • ••This study showed that tight glycaemiccontrol prevented diabetic retinopathy progression in Type I diabetics.
  • UK PROSPECTIVE DIABETES STUDY GROUP: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes. Lancet (1998) 352: 837–853.
  • ••This study showed that tight glycaemiccontrol prevented diabetic retinopathy progression in Type II diabetics.
  • EPIDEMIOLOGY OF DIABETES INTERVENTIONS AND COMPLICATIONS STUDY GROUP: Effect of intensive therapy on the microvascular complications of Type 1 diabetes mellitus. JAMA (2002) 287:2563–2569.
  • UK PROSPECTIVE DIABETES STUDY GROUP: Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. Br. Med. J. (1998) 317:703–713.
  • ORCHARD T, FORREST K, KULLER L et al.: Lipid and blood pressure treatment goals for Type 1 diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diab. Care (2001) 24:1053–1059.
  • LYONS T, JENKINS A, ZHENG D et al.:Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest. OphthalmoL Vi,s. Sci. (2004) 45:910–918.
  • DIABETIC RETINOPATHY STUDY RESEARCH GROUP: Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of diabetic retinopathy study (DRS) findings. DRS Report Number 8. Ophthalmology (1981) 88:583–600.
  • ••This study showed that panretinal laserphotocoagulation significantly reduced some complications of diabetic neovascularisation.
  • EARLY TREATMENT DIABETIC RETINOPATHY STUDY RESEARCH GROUP: Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report number 1. Arch. OphthalmoL (1985) 103:1796–1806.
  • ••This study showed that focal laserphotocoagulation significantly reduced some complications of diabetic ME.
  • EARLY TREATMENT DIABETIC RETINOPATHY STUDY RESEARCH GROUP: Early photocoagulation for diabetic retinopathy. ETDRS Report number 9. Ophthalmology (1991) 98:766–785.
  • VINE k The efficacy of additional argon laser photocoagulation for persistent, severe proliferative diabetic retinopathy. Ophthalmology (1985) 92:1532–1537.
  • GABBAY K: Hyperglycemia, polyol metabolism, and complications of diabetes mellitus. Ann. Rev. Med. (1975) 26:521–535.
  • AKAGI Y, YAJIMA Y, KADOR P et al.: Localization of aldose reductase in the human eye. Diabetes (1984) 33:562–566.
  • ASNAGHI V GERHARDINGER C, HOEHN T et al.: A role for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat. Diabetes (2003) 52:506–511.
  • SATO S, SECCHI E, LIZAK M et al.: Polyol formation and NADPH-dependent reductases in dog retinal capillary pericytes and endothelial cells. Invest. OphthalmoL Vis. Sci. (1999) 40:697–704.
  • DEL MONTE M, RABBANI R, DIAZ T et al.: Sorbitol, myo-inositol, and rod outer segment phagocytosis in cultured hRPE cells exposed to glucose. In vitro model of myo-inositol depletion hypothesis of diabetic complications. Diabetes (1991) 40:1335–1345.
  • LI W, TANG L, ZHOU Q et al.: DNA-synthesis regulation and correlation with inositol trisphosphate levels in cultured bovine retinal capillary pericytes. Exp. Eye Res. (1989) 49:677–683.
  • LI W, ZHOU Q, QIN M et al.: Reduced absolute rate of myo-inositol biosynthesis of cultured bovine retinal capillary pericytes in high glucose. Exp. Eye Res. (1991) 52:569–573.
  • SORBINIL RETINOPATHY TRIAL RESEARCH GROUP: A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch. Ophthalmol (1990) 108:1234–1244.
  • TROMP A, HOOYMANS J, BARENDSEN B, VAN DOORMAAL JJ: The effects of an aldose reductase inhibitor on the progression of diabetic retinopathy. Doc. Ophthalmol (1991) 78: 153–159.
  • ARAUZ-PACHECO C, RAMIREZ L, PRUNEDA L et al.: The effect of the aldose reductase inhibitor, ponalrestat, on the progression of diabetic retinopathy. J. Diabetes Complicat. (1992) 6:131–137.
  • VAN GERVEN J, BOOT J, LEMKES H, VAN BEST J: Effects of aldose reductase inhibition with tolrestat on diabetic retinopathy in a six months double blind trial. Doc. Ophthalmol. (1994) 87:355–365.
  • STEVENS M, HENRY D, THOMAS T et al.: Aldose reductase gene expression and osmotic dysregulation in cultured human retinal pigment epithelial cells. Am. J. Physiol (1993) 265:E428–E438.
  • OBROSOVA I, MINCHENKO A, VASUPURAM R et al.: Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes (2003) 52:864–871.
  • HAMADA Y, NAKUMURA J, NARUSE K et al.: Epalrestat, an aldose reductase inhibitor, reduces the levels of Nepsilon-(carboxymethyfilysine protein adducts and their precursors in erythrocytes from diabetic patients. Diab. Care (2000) 23:1539–1544.
  • CUSICK M, CHEW E, FERRIS Fl et al.:Effects of aldose reductase inhibitors and galactose withdrawal on fluorescein angiographic lesions in galactose-fed dogs. Arch. Ophthalmol. (2003) 121:1745–1751.
  • NISHIKAWA T, EDELSTEIN D, BROWNLEE M: The missing link: a single unifying mechanism for diabetic complications. Kidney Int. (2000) 58(Suppl 77):526–530.
  • ENGERMAN R, KERN T, LARSON M: Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosemia in dogs. Diabetologia (1994) 37:141–144.
  • DAGHER Z, PARK Y, ASNAGHI V et al.:Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy. Diabetes (2004) 53:2404–2411.
  • BROWNLEE M, VLASSARA H, CERAMI A: Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann. Intern. Med. (1984) 101:527–537.
  • FREEDMAN B, WUERTH J, CARTWRIGHT K et al.: Design and baseline characteristics for the aminoguanidine clinical trial in overt Type 2 diabetic nephropathy (ACTION II). Control Clin. Trials (1999) 20:493–510.
  • SCHMIDT A, YAN S, WAUTIER J-L, STERN D: Activation of receptor for advanced glycation end products. A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ. Res. (1999) 84:489–497.
  • SINGH R, BARDEN A, MORI T, BEILIN L: Advanced glycation end-products: a review. Diabetologia (2001) 44:129–146.
  • MAMPUTU J, RENIER G: Advanced glycation end-products increase monocyte adhesion to retinal endothelial cells through vascular endothelial growth factor-induced ICAM-1 expression: inhibitory effect of antioxidants. J. Leukocyte Biol. (2004) 75:1062–1069.
  • HAMMES H, MARTIN S, FEDERLIN K et al.: Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc. Natl Acad. Sci. USA (1991) 88:11555–11558.
  • KOWLURU R, ENGERMAN R, KERN T: Abnormalities of retinal metabolism in diabetes or experimental galactosemia, VIII: prevention by aminoguanidine. Curr. Eye Res. (2000) 21:814–819.
  • KERN T, ENGERMAN R: Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes (2001) 50:1636–1642.
  • BOLTON W, CATTRAN D, WILLIAMS M et al.: Randomized trial of an inhibitor of advanced glycation end products in diabetic nephropathy. Am. J. Nephrol. (2004) 24:32–40.
  • GIUGLIANO D, CERIELLO A, PAOLISSO G: Oxidative stress and diabetic vascular complications. Diabetes Care (1996) 19:257–267.
  • NISHIKAWA T, EDELSTEIN D, DU X et al.: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature (2000) 404:787–790.
  • INAGAKI Y, YAMAGISHI S, OKAMOTO T et al.: Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation. Diabetologia (2003) 46:284–287.
  • KUROKI M, VOEST E, AMANO S et al.: Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J. Clin. Invest. (1996) 98:1667–1675.
  • BURSELL S, CLERMONT A, AIELLO L et al.: High dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with Type I diabetes. Diabetes Care (1999) 22: 1245–1251.
  • BRIGNARDELLO E, BELTRAMO E, MOLINATTI P et al.: Dehydroepiandrosterone protects bovine retinal capillary pericytes against glucose toxicity. J. Endocrinol (1998) 158: 21–26.
  • KUNISAKI M, BURSELL S, CLERMONT A et al.: Vitamin E prevents diabetes-induced abnormal retinal blood flow via the diacylglycerol-protein kinase C pathway. Am. j Physiol (1995) 269:E239–E246.
  • GEY K: The antioxidant hypothesis of cardiovascular disease: epidemiology and mechanisms. Biochem. Soc. Trans. (1990) 18:1041–1045.
  • HOOGWERF B, YOUNG J: The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not. Cleve. Clin. J. Med. (2000) 67:287–293.
  • PRUTHI S, ALLISON T, HENSRUD D: Vitamin E supplementation in the prevention of coronary heart disease. Mayo Clin. Proc. (2001) 76:1131–1136.
  • MILLEN A, GRUBER M, KLEIN R et al.: Relations of serum ascorbic acid and alpha-tocopherol to diabetic retinopathy in the Third National Health and Nutrition Examination Survey. Am. J. Epidemiol. (2003) 158:225–233.
  • OGURA Y, KIRYU J, TAKAHASHI K et al.: Visual improvement in diabetic macular edema by hyperbaric oxygen treatment. Nippon Ganka Gakkai Zasshi (1988) 92:1456–1460.
  • KROTT R, HELLER R, AINSENBREY S et al.: Adjunctive hyperbaric oxygenation in macular edema of vascular origin. Undersea Hyperb. Med. (2000) 27:195–204.
  • HARRIS A, AREND O, DANIS R et al.: Hyperoxia improves contrast sensitivity in early diabetic retinopathy. Br. J. OphthalmoL (1996) 80: 209–213.
  • NGUYEN Q, SHAH S, ANDEN E et al.: Supplemental oxygen improves diabetic macular edema: a pilot study. Invest. OphthalmoL Vis. Sci. (2004) 45:617–624.
  • •This recent study suggested a novel approach to treating ME with supplemental oxygen.
  • MILLER J, ADAMIS A, AIELLO L: Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diab. Metab. Rev. (1997) 13:37–50.
  • ISHIDA S, USUI T, YAMASHIRO K et al.: VEGF164 is proinflammatory in the diabetic retina. Invest. OphthalmoL Vis. (2003) 44:2155–2162.
  • ADAMIS A, SHIMA D, YEO T et al.: Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem. Biophys. Res. Commun. (1993) 193:631–638.
  • SIMORRE-PINATEL V, GUERRIN M, CHOLLET P et al.: Vasculotropin-VEGF stimulates retinal capillary endothelial cells through an autocrine pathway. Invest. OphthalmoL Vis. Sci. (1994) 35:3393–3400.
  • ADAMIS A, MILLER J, BERNAL M et al.: Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. OphthalmoL (1994) 118: 445–450.
  • PEER J, FOLBERG R, ITIN A et al.: Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy. Br. J. OphthalmoL (1996) 80:241–245.
  • MALECAZE F, CLAMENS S, SIMORRE-PINATEL V et al.: Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch. OphthalmoL (1994) 112:1476–1482.
  • AIELLO L, BURSELL S-E, CLERMONT A et al.: Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective 0-isoform-selective inhibitor. Diabetes (1997) 46:1473–1480.
  • MELDER R, KOENIG G, WITWER B et al.: During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat. Med. (1996) 2:992–997.
  • DETMAR M, BROWN L, SCHON M et al.: Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J. Invest. DermatoL (1998) 111:1–6.
  • LU M, PEREZ L, MAN et al.: VEGF increases retinal vascular ICAM-1 expression in vivo. Invest. OphthalmoL Vis. Sci. (1999) 40:1808–1812.
  • MIYAMOTO K, KHOSROF S, BURSELL S et al.: Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am. J. PathoL (2000) 156:1733–1739.
  • PRESTA L, CHEN H, O'CONNOR S et al.: Humanization of anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. (1997) 57:4593–4599.
  • ADAMIS A, SHIMA D, TOLENTINO M et al.: Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch. OphthalmoL (1996) 114:66–71.
  • INOGUCHI T, BATTAN R, HANDLER E et al.: Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc. Natl. Acad. Sci. USA (1991) 89:11059–11063.
  • XIA P, INOGUCHI T, KERN TS et al.: Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes (1994) 43:1122–1129.
  • KOYA D, KING G: Protein kinase C activation and the development of diabetic complications. Diabetes (1998) 47:859–866.
  • TAHER M, GARCIA J, NATARAJAN V: Hydroperoxide-induced diacylglycerol formation and protein kinase C activation in vascular endothelial cells. Arch. Biochem. Biophys. (1993) 303:260–266.
  • NAGPALA P, MALIK A, VUONG P, LUM H: Protein kinase C bl overexpression augments phorbol ester-induced increase in endothelial permeability. J. Cell PhysioL (1996) 166:249–255.
  • HUANG Q, YUAN Y: Interaction of PKC and NOS in signal transduction of microvascular hyperpermeability. Am. J. PhysioL (1997) 273:H2442–H2451.
  • PARK J-Y, TAKAHARA N, GABRIELE A et al.: Induction of endothelin-1 expression by glucose: an effect of protein kinase C activation. Diabetes (2000) 49:1239–1248.
  • XIA P, AIELLO L, ISHII H et al.: Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J. Clin. Invest. (1996) 98:2018–2026.
  • WILLIAMS B, GALLAGHER B, PATEL H et al.: Glucose induced protein kinase C activation regulates vascular permeability factor (VEGF) mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes (1997) 46: 1497–1503.
  • CHIBBER R, BEN-MAHMUD B, COPPINI D et al.: Activity of core 2 GlcNAc (B1,6) transferase is higher in polymorphonuclear leukocytes from diabetic patients compared with age-matched control subjects. Diabetes (2000):1724–1730.
  • CHIBBER R, BEN-MAHMUD B, MANN G et al.: Protein kinase C 02-dependent phosphorylation of core 2 GlcNAc-T promotes leukocyte endothelial cell adhesion. Diabetes (2003) 52:1519–1527.
  • TAKAHARA N, CLERMONT A, KAGOKAWA H et al.: Transgenic mice overexpressing protein kinase C isoform mimicked the early changes of diabetes (Abstract). Diabetes (1999) 48:A138.
  • SEO M, KWAK N, OZAKI H et al.: Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am. J. PathoL (1999) 154:1743–1753.
  • FABBRO D, RUETZ S, BODIS S et al.: PKC412 - a protein kinase inhibitor with a broad therapeutic potential. Anti-Cancer Drug Des. (2000) 15:17–28.
  • PROPPER D, MCDONALD A, MAN P et al.: Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. Clin. OncoL (2001) 19:1485–1492.
  • CAMPOCHIARO P, C99-PKC412-003 STUDY GROUP: Reduction of diabetic macular edema by oral administration of the 451 Expert Op/n. Emerging Drugs (2005) 10(2) kinase inhibitor PKC412. Invest. Ophthalmol. Vis. Sci. (2004) 45:922–931.
  • JIROUSEK M, GILLIG J, GONZALEZ C et al.: (S)-13-[(climethylamino)methy1]-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H,13H- dibenzo [e,k] pyrrolo [3,4- h] [1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C. J. Med. Chem. (1996) 39:2664–2671.
  • ISHII H, JIROUSEK M, KOYA D et al.:Amelioration of vascular dysfunctions in diabetic rats by an oral PKC inhibitor. Science (1996) 272:728–731.
  • NONAKA A, KIRYU J, TSUJIKAWA A et al.: PKC-beta inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats. Invest. Ophthalmol. Vis. Sci. (2000) 41:2702–2706.
  • ABIKO T, ABIKO A, CLERMONT A et al.: Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes: role of oxidants and protein kinase-C activation. Diabetes (2003) 52:829–837.
  • DANIS R, BINGAIVIAN D, JIROUSEK M, YANG Y: Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKC inhibition with LY333531. Invest. Ophthalmol. Vis. Sci. (1998) 39:171–179.
  • AIELLO L, BURSELL S, DEVRIES T et al.: Protein kinase C selective inhibitor LY333531 ameliorates abnormal retinal hemodynamics in patients with diabetes (Abstract). Diabetes (1999) 48:A19.
  • MORI K, DUH E, GEHLBACK P et al.: Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J. Cell Invest. (2001) 188:253–263.
  • DAWSON D, VOLPERT O, GILLIS P et al.: Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science (1999) 285:245–248.
  • STELLMACH V, CRAWFORD S, ZHOU W, BOUCK N: Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc. Natl. Acad. Sci. USA (2001) 98:2593–2597.
  • GAO G, LI Y, ZHANG D et al.: Unbalanced expression of VEFG and PEDF in ischemia induced retinal neovascularization. FEBS Lett. (2001) 489:270–276.
  • OHNO-MATSUI K, MORITA I, TOMBRAN-TINK J et al.: Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF. J. Cell Physiol. (2001) 189:323–333.
  • DUH E, YANG H, SUZUMA I et al.: Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest. Ophthalmol. Vis. Sci. (2002) 43:821–829.
  • DUH E, YANG H, HALLER J et al.: Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis. Am. J. Ophthalmol. (2004) 137:668–674.
  • SPRANGER J, OSTERHOFF M, REIMANN M et al.: Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes (2001) 50:2641–2645.
  • OGATA N, NISHIKAWA T, NISHIMURA T et al.: Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. Am. J. Ophthalmol. (2002) 134:348–353.
  • MALLET B, VIALETTES B, HAROCHE S et al.: Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201-995. Diabetes MetaboL (1992) 8:438–444.
  • GRANT M, MAMES R, FITZGERALD C et al.: The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy. Diabetes Care (2000) 23:504–509.
  • POULSEN J: The Houssay phenomenon in man: recovery from retinopathy in a case of diabetes with Simmond's disease. Diabetes (1953) 2:7–12.
  • GRANT M, MAMES R, FITZGERALD C et al.: Insulin-like growth factor 1 acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor. Diabetologia (1993) 36:282–291.
  • SMITH L, KOPCHICK J, CHEN W et al.: Essential role of growth hormone in ischemia-induced retinal neovascularization. Science (1997) 276:1706–1709.
  • KONDO T, VICENT D, SUZUMA K et al.: Knockout of insulin and IGF-1 receptors on vascular endothelial cells protects against retinal neovascularization. Clin. Invest. (2003) 111:1835–1842.
  • SIMO R, LECUBE A, SARAROLS L et al.: Deficit of somatostatin-like immunoreactivity in the vitreous fluid of diabetic patients: possible role in the development of proliferative diabetic retinopathy. Diab. Care (2002) 25:2282–2286.
  • MCCOMBE M, LIGHTMAN S, ECKLAND D et al.: Effect of a long-acting somatostatin analogue (BIM23014) on proliferative diabetic retinopathy: a pilot study. Eye (1991) 5:569–575.
  • GROWTH HORMONE ANTAGONIST For PROLIFERATIVE DIABETIC RETINOPATHY STUDY GROUP: The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology (2001) 108:2266–2272.
  • CHEW E, KLEIN M, FERRIS Fl et al.: Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. ETDRS report 22. Arch. Ophthalmol. (1996) 114:1079–1084.
  • KLEIN B, MOSS S, KLEIN R, SURAWICZ T: The Wisconsin Epidemiologic Study of Diabetic Retinopathy, XII: relationship of serum cholesterol to retinopathy and hard exudates. Ophthalmology (1991) 98:1261–1265.
  • FONG D, SEGAL P, MYERS F et al.: Subretinal fibrosis in diabetic macular edema. ETDRS report 23. Arch. Ophthalmol. (1997) 115:873–877.
  • CUSICK M, CHEW E, CHAN C-C et al.: Histopathology and regression of retinal hard exudates in diabetic retinopathy after reduction of elevated serum lipid levels. Ophthalmology (2003) 110:2126–2133.
  • GORDON B, CHANG S, KAVANAGH M et al.: The effect of lipid lowering on diabetic retinopathy. Am. J. Ophthalmol. (1991) 112:385–391.
  • MIYAHARA S, KIRYU J, YAMASHIRO K et al.: Simvastatin inhibits leukocyte accumulation and vascular permeability in the retinas of rats with streptozotocin-induced diabetes. Am. J. Pathol. (2004) 164:1697–1706.
  • GUPTA A. GUPTA S., BHANSALI A: Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am. J. Ophthalmol. (2004) 137:675–682.
  • •This recent study lends further support to the growing belief that statin drugs might help with the management of DR.
  • SEN K, MISRA A, KUMAR A, PANDEY R: Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diab. Res. Clin. Pract. (2002) 56:1–11.
  • MASFERRER J, LEAHY K, KOKI A et al.: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. (2000) 60:1306–1311.
  • LEAHY K, ORNBERG R, WANG Y et al.: Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. (2002) 62:625–631.
  • TSUJII M, KAWANO S, TSUJII S et al.: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell (1998) 93:705–716.
  • JONES J, WANG H, PESKAR B et al.: Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med. (1999) 5:1418–1423.
  • DEGI R, THORE C, BARI F et al.: Ischemia increases prostaglandin H synthase-2 levels in retina and visual cortex in piglets. Graefes Arch. Clin. Exp. Ophthalmol. (2001) 239:59–65.
  • SENNLAUB F, VALAMANESH F, VAZQUEZ-TELLO A et al.: Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy. Circulation (2003) 108:198–204.
  • TOLENTINO M, ADAMIS A: Angiogenic factors in the development of diabetic iris neovascularization and retinopathy. Int. Ophthalmol. Clin. (1998) 38:77–94.
  • CHATURVEDI N, SJOLIE A-K, STEPHENSON J et al.: EUCLID Study Group. Effect of lisinopril on progression of retinopathy in normotensive people with Type 1 diabetes. Lancet (1998) 351: 28–31.
  • UK PROSPECTIVE DIABETES STUDY GROUP: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 39. Br. Med. J. (1998) 317:713–772.
  • WILLIAMS B, BAKER A, GALLAGHER B, LODWICK D: Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension (1995) 25: 913–917.
  • OTANI A, TAKAGI H, SUZUMA K, HONDA Y: Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ. Res. (1998) 82:619–628.
  • MORAVSKI C, KELLY D, COOPER M et al.: Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Hypertension (2000) 36:1099–1104.
  • GILBERT R, KELLY D, COX A et al.: Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia (2000) 43:1360–1367.
  • TIKELLIS C, COOPER M, TWIGG S et al.: Connective tissue growth factor is up-regulated in the diabetic retina: amelioration by angiotensin-converting enzyme inhibition. Endocrinology (2004) 145:860–866.
  • ZHANG J-Z, GAOL, WIDNESS M et al.: Captopril inhibits glucose accumulation in retinal cells in diabetes. Invest. Ophthalmol. Vis. Sci. (2003) 44:4001–4005.
  • HEART OUTCOMES PREVENTION EVALUATION (HOPE) STUDY INVESTIGATORS: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet (2000) 355:253–259.
  • ESTACIO R, JEFFERS B, GIFFORD N, SCHRIER R: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and Type 2 diabetes. Diabetes Care (2000) 23:B54–B64.
  • NAGISA Y, SHINTANI A, NAKAGAWA S et al.: The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats. Diabetologia (2001) 44:883–888.
  • KNUDSEN S, BEK T, POULSEN P et al.: Effects of losartan on diabetic maculopathy in Type 2 diabetic patients: a randomized, double-masked study. J. Int. Med. (2003) 254:147–158.
  • JOUSSEN A, POULAKI V, MITSIADES N et al.: Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB (2002) 16:438–440.
  • THE DAMAD STUDY GROUP: Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. Diabetes (1989) 38:491–498.
  • BROUTY-BOYN D, ZETTER B: Inhibition of cell motility by interferon. Science (1980) 208:516–518.
  • SIDKY Y, BORDEN E: Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res. (1987) 47:5151–5161.
  • WHITE C, SONDHEIMER H, CROUCH E et al.: Treatment of pulmonary hemangiomatosis with recombinant interferon a-2a. N EngL J. Med. (1989) 320:1197–1200.
  • EZEKOWITZ R, MULLIKEN J, FOLKMAN J: Interferon a-2a therapy for life-threatening hemangiomas of infancy. N Engl. J. Med. (1992) 326:1456–1463.
  • FUNG W: Interferon a 2a for treatment of age-related macular degeneration. Am. J. Ophthalmol. (1991) 112:349–350.
  • ENGLER C, SANDER B, VILLUMSEN J, LUND-ANDERSON H: Interferon a 2a modifies the course of subfoveal and juxtafoveal choroidal neovascularization. Br. J. Ophthalmol. (1994) 78:749–753.
  • CHAN C, KEMPIN S, NOBLES, PALMER G: The treatment of choroidal neovascular membranes by a interferon. An efficacy and toxicity study. Ophthalmology (1994) 101:289–300.
  • MILLER J, STINSON W, FOLKMAN J: Regression of experimental iris neovascularization with systemic a-interferon. Ophthalmology (1993) 100:9–14.
  • JAAKKOLA A, ANTTILA P, INNONEN I: Interferon a-2a in the treatment of exudative senile macular degeneration. Acta. Ophthalmol. (1994) 72:545–549.
  • THOMAS M, IBANEZ H: Interferon a-2a in the treatment of subfoveal choroidal neovascularization. Am. J. Ophthalmol. (1993) 115:563–568.
  • THOELEN A, MENOZZI M, HUBER C, MESSMER E: Treatment of choroidal neovascularization in age-related macular degeneration with interferon a-2a: a short term, nonrandomized pilot study. Ger. J. Ophthalmol. (1995) 4:137–143.
  • PHARMACOLOGICAL THERAPY FOR MACULAR DEGENERATION STUDY GROUP: Interferon a-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Arch. Ophthalmol (1997) 115:865–872.
  • LEIBOVITCH I, LOEWENSTEIN A, ALSTER Y et al.: Interferon a-2a for proliferative diabetic retinopathy after complete laser panretinal photocoagulation treatment. Ophthalmic Surg. Lasers Imaging (2004) 35:16–22.
  • MIYAMOTO K, KHOSROF S, BURSELL S et al.: Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc. Natl Acad. Sci. USA (1999) 96:10836–10841.
  • BAROUCH F, MIYAMOTO K, ALLPORT J et al.: Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. Invest. Ophthalmol lTzs. Sci. (2000) 41:1153–1158.
  • MIYAMOTO K, HIROSHIBA N, TSUJIKAWA A et al.: In vivo demonstration of increased leukocyte entrapment in retinal microcirculation of diabetic rats. Invest. Ophthalmol. Vis. Sci. (1998) 39:2190–2194.
  • JOUSSEN A, MURATA T, TSUJIKAWAA et al.: Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am. J. PathoL (2001) 158:147–152.
  • XU Q, QAUM T, ADAMIS A: Sensitive blood-retinal barrier breakdown quantitation using Evans blue. Invest. Ophthalmol. Vis. Sci. (2001) 42:789–794.
  • ADAMIS A: Is diabetic retinopathy an inflammatory disease? Br. J. Ophthalmol (2002) 86:363–366.
  • FRIEDLANDER M, THEESFELD C, SUGITA M et al.: Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc. Natl Acad. Sci. USA (1996) 93:9764–9769.
  • HAMMES H, BROWNLEE M, JONCZYK A et al.: Subcutaneous injection of a cyclic peptide antagonist of neovascularization. Nat. Med. (1996) 2:529–533.
  • WOESNNER J: The matrix metalloproteinase family. Academy Press, San Diego, USA (1998):1–14.
  • STEEN B, SEJERSEN S, BERGLIN L et al.: Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes. Invest. Ophthalmol Vis. Sci. (1998) 39:2194–2200.
  • NODA K, SUSUMU I, INOUE M et al.: Production and activation of matrix metalloproteinase-2 in proliferative diabetic retinopathy. Invest. Ophthalmol lTzs. Sci. (2003) 44:2163–2170.
  • JIN M, KASHIWAGI K, IIZUKA Y et al.: Matrix metalloproteinases in human diabetic and nondiabetic vitreous. Retina (2001) 21:28–33.
  • STERNLICHT M, WERB Z: How matrix metalloproteinases regulate cell behavior. Ann. Rev. Cell Dev. Biol. (2001)463–516
  • KINOSHITA T, SATO H, OKADA A et al.: TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads. J. Biol. Chem. (1998) 273:16098–16103.
  • BUTLER G, BUTLER M, ATKINSON S et al.: The TIMP-2 membrane Type 1 metalloproteinase 'receptor' regulates the concentration and efficient activation of progelatinase A: a kinetic study. J. Biol. Chem. (1998) 273:871–880.
  • OZERDEM U, MACH-HOFACRE B, KEEFE K et al.: The effect of prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinases, on posttraumatic proliferative vitreoretinopathy. Ophthalmic Res. (2001) 33:20–23.
  • OZERDEM U, MACH-HOFACRE B, VARKI N et al.: The effect of prinomastat (AG2240), a synthetic inhibitor of matrix metalloproteinases, on uveal melanoma rabbit model. Curr. Eye Res. (2002) 24:86–91.
  • CHENG L, RIVERO M, GARCIA G et al.: Evaluation of intraocular pharmacokinetics and toxicity of prinomastat (AG3340) in the rabbit. J. Ocular Pharm. Ther. (2001) 17:295–304.
  • ZHANG K, MCDERMOTT C, BREKKEN J et al.: Ocular bioavailability and pharmacokinetics of AG3340, a potent MMP inhibitor with antiangiogenic activity, following oral administration. Proc. NY Acad. Sci. (1998).
  • COLLIER M, YUEN B, BANSAL S et al.: Phase I study of the matrix metalloprotease inhibitor AG3340 given in a single dose to healthy volunteers. Proc. Am. Assoc. Cancer Res. (1997) 38:A1491.
  • GARCIA C, BARTSCH D, RIVERO M et al.: Efficacy of prinomastat (AG3340), a matrix metalloprotease inhibitor, in treatment of retinal neovascularization. Curr. Eye Res. (2002) 24:33–38.
  • CHALLA J, GILLIES M, PENFOLD P et al.: Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust. N Z. J. Ophthalmol (1998) 26:277–281.
  • ISHIBASHI T, MIKI K, SORGENTE N et al.: Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch. Ophthalmol (1985) 103:708–711.
  • PENFOLD P, GYORY J, HUNYOR A, BILLSON F: Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust. N Zeal. J. Ophthalmol (1995) 23:293–298.
  • WANG Y, FRIEDRICHS U, EICHLER W et al.: Inhibitory effects of triamcinolone acetonide on bEGF-induced migration and tube formation in choroidal microvascular endothelial cells. Graefis Arch. Clin. Exp. Ophthalmol (2002) 240:42–48.
  • FOLKMAN J, INGBER D: Angiostatic steroids. Method of discovery and mechanism of action. Ann. Surg (1987) 206:374–383.
  • PENFOLD P, WEN L, MADIGAN M et al.: Modulation of permeability and adhesion molecule expression by human choroidal endothelial cells. Invest. Ophthalmol. Vis. Sci. (2002) 43:3125–3130.
  • PENFOLD P, WONG J, GYORY J et al.: Effects of triamcinolone acetonide on microglial morphology and quantitative expression of MHC-II in exudative age-related macular degeneration. Clin. Exp. Ophthalmol (2001) 29:188–192.
  • PENFOLD P, WEN L, MADIGAN M et al.: Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 ICAM-1 expression of the ECV304 cell line: implications for macular degeneration. Exp. Immunol (2000) 121:458–465.
  • PENN J, RAJARATNAM V, COLLIER R, CLARK A: The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. (2001) 42:283–290.
  • DANIS R, BINGAMAN D, YANG Y, LADD L: Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology (1996) 103: 2099–2104.
  • JONAS J, HAYLER J, SOFKER A, PANDA-JONES S: Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am. J. Ophthalmol. (2001) 131:468–471.
  • JONAS J, HAYLER J, SOFKER A et al.: Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone. J. Glaucoma (2001) 10:284–287.
  • JONAS J, SOFKER k Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am. J. Ophthalmol. (2001) 132:425–427.
  • JONAS J, DEGENRING R: [Intravitreal injection of crystalline triamcinolone acetonide in the treatment of diffuse diabetic macular oedema]. lain. Monatsbl Augenheilkd (2002) 219:429–432.
  • MARTIDIS A, DUKER J, GREENBERG P et al.: Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology (2002) 109:920–927.
  • JONAS J, KREISSIG I, SOFKER A, DEGENRING R: Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch. Ophthalmol. (2003) 121:57–61.
  • JONAS J, KREISSIG I, HUGGER P et al.: Intravitreal triamcinolone acetonide for exudative age-related macular degeneration. Br. J. Ophthalmol. (2003) 87:462–468.
  • MASSIN P, AUDREN F, HAOUCHINE B et al.: Intravitreal triamcinolone acetonide for diabetic diffuse macular edema. Preliminary results of a prospective controlled trial. Ophthalmology (2004) 111:218–225.
  • •This is one of the first prospective studies to evaluate the growing tendency to use intravitreal triamcinolone acetonide in the treatment of ME.
  • SPEICHER M, DANIS R, CRISWELL M, PRATT L: Pharmacologic therapy for diabetic retinopathy. Expert Opin. Emerg. Drugs (2003) 8:239–250.
  • KIM N, YU H, YU Y, CHUNG H: Long-term effect of plasmin on the vitreolysis in rabbit eyes. Korean J. Ophthalmol. (2004) 18:35–40.
  • HIKICHI T, YANAGIYA N, KADO M et al.: Posterior vitreous detachment induced by injection of plasmin and sulfur hexafluoride in the rabbit vitreous. Retina (1999) 19:55–58.
  • GANDORFER A, PUTZ E, WELGE-LUSSEN U et al.: Ultrastructure of the vitreoretinal interface following plasmin assisted vitrectomy. Br. J. Ophthalmol. (2001) 85:6–10.
  • GANDORFER A, ROHLEDER M, SETHI C et al.: Posterior vitreous detachment induced by microplasmin. Invest. Ophthalmol. Vis. Sci. (2004) 45:641–647.
  • MEN G, PEYMAN G, GENAIDY M et al.: The role of recombinant lysine-plasminogen and recombinant urokinase and sulfur hexafluoride combination in inducing posterior vitreous detachment. Retina (2004) 24:199–209.
  • TEZEL T, PRIORE L, KAPLAN H: Posterior vitreous detachment with dispase. Retina (1998) 18:7–15.
  • AZZOLINI C, D'ANGELO A, MAESTRANZI G et al.: Intrasurgical plasmin enzyme in diabetic macular edema. Am. J. Ophthalmol. (2004) 138:560–566.
  • •This recent study expanded on the increasing body of evidence that a chemically induced vitreous detachement might help in the treatment of DR.

Websites

  • http://www.eyetk.com/clinical/ clinicalindex.asp. EYETECH PHARMACEUTICALS (2005).
  • http://www.Ophthalmologytimes.com.cn/ articles/ articleDetail.jsp?MAG ARTICLESID=692 48cLANGUAGEID=2. GROVES N: Ruboxistaurin slows central DME, does not halt progression (2005).
  • http://www.clinicaltrials.gov/ct/gui/show/ NCT00090519;jsessionid=400F595E5DD C845218F5C5FAB3FCC2D5?ordet=7.
  • http://www.clinicaltrials.gov/ct/show/ NCT00050479?ordet=87.
  • http://www.atacand.com/index.asp?did=34618caid=320798c11=8c12= 8cmid=.
  • http//:www.controldelivery.com/ PRMay72003.htm;Accessed 10/7/2004. CONTROL DELIVERY SYSTEMS: Analysis of 12-month data from diabetic macular edema clinical trail sponsored by Bausch & Lomb and Control Delivery Systems to be presented at ARVO 2003. Press release (2003).
  • http://www.shareholder.com/agn/ ReleaseDetail.cfm?ReleaseID=123213.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.